STOCKHOLM, SWEDEN — June 17, 2002 —
The new investigational COX-2 inhibitor etoricoxib is showing promise with respect to providing relief in many painful conditions, including back pain, rheumatoid arthritis (RA), and acute gouty arthritis (AGA). The drug also appears to have a favorable renovascular safety profile. Several studies on etoricoxib were presented here this week at the Annual European Congress of Rheumatology (EULAR).
In a study led by Dr. J. A. Boice from the department of clinical research at Merck & Co., Inc., Rahway, United States, 150 adults with AGA of less than 48 hours’ duration were randomized to treatment with etoricoxib 120 mg daily or indomethacin 50 mg TID for eight days. Response was equally fast and effective with both drugs, according to both the patients’ and the investigators’ assessments of pain, tenderness, and inflammation.
Another study, led by Dr. G. P. Geba from the clinical development department of Merck & Co in West Point, United States, compared treatment with etoricoxib 60 and 90 mg to placebo in 325 patients with chronic low back pain. After three months, patients in both etoricoxib groups reported significantly reduced pain and disability compared to placebo patients.
Dr. S. P. Curtis, also from the department of clinical research at Merck & Co., Inc., Rahway, led another study in which 891 RA patients were randomized to treatment with etoricoxib 90 mg daily, naproxen 500 mg BID, or placebo. Among the 687 patients who completed the 12 week study, patients on etoricoxib and naproxen had significantly greater improvement than placebo patients on parameters that included counts of tender and swollen joints, patient and investigator assessment of disease activity, Stanford Health Assessment Questionnaire (HAQ) results, American College of Rheumatology (ACR) 20 response criteria, and patient assessments of pain. Both treatments were well tolerated.
e-Med Tools
קצר קולע וממוקד
e-Med סמינרים
אי-מד תחקירים
Medscape Tools
Journal Club
מרכזי מידע ושירות
Facebook
מידע למפרסם
מאגר תרופות
מאגר אנשי המקצוע
אינדקס שימושי
חדשות משה"ב
eMed HealthClub
מחקרים קליניים
השאירו תגובה
רוצה להצטרף לדיון?תרגישו חופשי לתרום!